Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
05/08/2026 13:21
BRIEF-HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians Aug 5 (Reuters) - HLS Therapeutics Inc HLS.TO:
HLS THERAPEUTICS PROVIDES UPDATE ON NILEMDO™ MARKET ACCESS
HLS THERAPEUTICS - SECURES NILEMDO REIMBURSEMENT WITH PRIVATE PAYERS COVERING 80% OF PRIVATELY INSURED CANADIANS
HLS THERAPEUTICS - CANADA'S DRUG AGENCY COMMITTEE UNANIMOUSLY RECOMMENDS NILEMDO REIMBURSEMENT BY PUBLIC DRUG PLANS
HLS THERAPEUTICS - REMAINDER OF PRIVATE PAYER NILEMDO AGREEMENTS TO TAKE EFFECT IN Q3 2026
Source text: ID:nCNWXgXPra
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group